#1 Clinical Trials Search in Europe

Explore popular drugs in clinical trials

Check which drugs are currently being frequently studied.

See also our rare diseases glossary and popular diseases list.

Starting by letter

To open the drugs glossary, select a letter from the list below.

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All drugs

Most popular drugs

The list below features the most popular substances currently involved in ongoing clinical trials.

Drug trials
Pembrolizumab 441
Sodium Chloride 403
Carboplatin 329
Cisplatin 274
Paclitaxel 245
Fluorouracil 226
Oxaliplatin 218
Nivolumab 205
Dexamethasone 203
Rituximab 189
Cyclophosphamide 183
Durvalumab 157
Bevacizumab 157
Paracetamol 154
Capecitabine 152
Atezolizumab 145
Docetaxel 127
Prednisone 125
Tocilizumab 120
Prednisolone 116
Gemcitabine 114
Venetoclax 113
Etoposide 113
Mycophenolate Mofetil 111
Pemetrexed 109
Doxorubicin Hydrochloride 104
Lenalidomide 97
Infliximab 93
Ipilimumab 89
Acetylsalicylic Acid 87
Folinic Acid 87
Semaglutide 86
Placebo 83
Paclitaxel Albumin-Bound 81
Methotrexate 77
Cytarabine 77
Daratumumab 77
Fludarabine Phosphate 75
Calcium Folinate 74
Letrozole 73
Bortezomib 70
Olaparib 70
Gemcitabine Hydrochloride 68
Dapagliflozin 66
Obinutuzumab 65
Trastuzumab 65
Azacitidine 65
Fulvestrant 62
Cetuximab 61
Tacrolimus 61
Methylprednisolone 61
Lenvatinib 60
Irinotecan 58
Irinotecan Hydrochloride Trihydrate 58
Vincristine Sulfate 57
Temozolomide 56
Cemiplimab 54
Trastuzumab Deruxtecan 53
Enzalutamide 51
Apixaban 49
Dexamethasone Sodium Phosphate 49
Codeine Phosphate 48
Betamethasone Sodium Phosphate 48
Lidocaine Hydrochloride Monohydrate 47
Exemestane 47
Buclizine Hydrochloride 46
Anastrozole 46
Potassium Chloride 46
Empagliflozin 46
Hydrocortisone 45
Lidocaine Hydrochloride 45
Amoxicillin 44
Ribociclib 44
Doxorubicin 43
Pertuzumab 43
Adalimumab 43
Clopidogrel 42
Ruxolitinib 41
Tenofovir Alafenamide 41
Rivaroxaban 41
Abemaciclib 41
Ibrutinib 40
Oxygen 40
Pomalidomide 40
Clavulanic Acid 39
Atorvastatin 39
Ropivacaine Hydrochloride 39
Metformin Hydrochloride 39
Ifosfamide 38
Carfilzomib 38
Palbociclib 38
Propofol 38
Bendamustine Hydrochloride 38
Emtricitabine 37
Acalabrutinib 37
Dostarlimab 37
Cyclophosphamide Monohydrate 37
Pemetrexed Disodium 37
Dexamethasone Phosphate 36
Sulfamethoxazole 36

New drugs in trials

The list below features the new substances involved to ongoing clinical trials.

#1 AZD0120

Clinical trials are investigating AZD0120 in people with relapsed or refractory multiple myeloma, a cancer that has returned or no longer responds to treatment.

2 weeks ago
#2 STREPTOCOCCUS VIRIDANS

Clinical trials investigating "STREPTOCOCCUS VIRIDANS" are studying whether a related study treatment can reduce respiratory infections in children.

2 weeks ago
#3 STREPTOCOCCUS PYOGENES

Clinical trials investigating STREPTOCOCCUS PYOGENES are studying a treatment called PMBL (Ismigen) in children with respiratory tract infections.

2 weeks ago
#4 AZD1163

Clinical trials are investigating AZD1163 in adults with moderately to severely active rheumatoid arthritis.

2 weeks ago
#5 AZD5335

Clinical trials are investigating AZD5335 in women with advanced platinum-resistant epithelial ovarian cancer.

2 weeks ago
#6 IMB 101

Clinical trials are studying NAV-240 in adults with moderate-to-severe hidradenitis suppurativa.

2 weeks ago

Drugs starting by j

  • 1 

    Jab-21822

    ,

    JAB-21822, also known as glecirasib, is an investigational drug currently being studied in various clinical trials for the treatment of advanced solid tumors, particularly those harboring KRAS G12C mutations. This article provides an overview of the ongoing research on JAB-21822, its potential benefits, and its role in combating different types of cancer.

    Related diseases and areas:

  • 1 

    Jk06

    ,

    A new drug called JK06 is currently being studied in clinical trials for patients with advanced or metastatic cancer that cannot be surgically removed. This article will provide an overview of the ongoing research, explaining the purpose of the study, how it’s conducted, and what researchers hope to learn about JK06’s potential in cancer treatment.

    Related diseases and areas:

  • 1 

    Jk08

    ,

    JK08, a novel recombinant fusion protein, is currently undergoing clinical trials for patients with unresectable locally advanced or metastatic cancer. This groundbreaking study aims to evaluate the safety, effectiveness, and potential of JK08 in treating various types of solid tumors. The trial involves both monotherapy and combination treatments, offering hope for patients with difficult-to-treat cancers.

    Related diseases and areas:

  • 1 

    Jnj-64042056

    ,

    A groundbreaking clinical trial is underway to evaluate the effectiveness of JNJ-64042056, a new drug designed to target phosphorylated tau in individuals with preclinical Alzheimer’s disease. This study aims to assess the drug’s impact on cognitive decline and brain tau burden, offering hope for early intervention in Alzheimer’s disease progression.

    Related diseases and areas:

  • 2 

    JNJ-75276617

    , ,

    A clinical trial is currently investigating JNJ-75276617, a promising new drug for pediatric and young adult patients with relapsed or refractory acute leukemias that have specific genetic alterations (KMT2A, NPM1, or nucleoporin). This Phase I/Ib study aims to determine the optimal dosage of JNJ-75276617 when combined with conventional chemotherapy. The trial focuses on patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and acute leukemia of ambiguous lineage who haven’t responded adequately to previous treatments. By testing different dosages and monitoring safety, researchers hope to find effective treatment options for these challenging cases of leukemia.

    Related diseases and areas:

  • 8 

    Jnj-77242113

    , ,

    JNJ-77242113 is an investigational drug currently being studied in clinical trials for its potential in treating moderate-to-severe plaque psoriasis and ulcerative colitis. This article provides an overview of the ongoing research, focusing on the drug’s efficacy, safety, and potential benefits for patients with these chronic inflammatory conditions.

    Related diseases and areas:

  • 1 

    Jnj-81241459

    ,

    A new clinical trial is underway to assess the effectiveness and safety of JNJ-81241459, a potential breakthrough medication for individuals suffering from moderate to severe plaque psoriasis. This Phase 2b study aims to compare different doses of the drug against a placebo, offering hope for improved treatment options for those affected by this chronic skin condition.

    Related diseases and areas:

  • 1 

    Jtt-861 Monohydrochloride Dihydrate

    ,

    This article discusses a Phase 2a clinical trial investigating the use of JTT-861 Monohydrochloride Dihydrate in patients with heart failure with reduced ejection fraction (HFrEF). The study aims to evaluate the efficacy, safety, and tolerability of JTT-861 when administered for 12 weeks. This multicenter, randomized, double-blind, placebo-controlled trial involves approximately 300 participants and compares two different doses of JTT-861 against a placebo.

    Related diseases and areas:

  • 1 

    Juniper Berry Oil

    ,

    A recent clinical trial is investigating the effectiveness of Juniper Berry Oil, specifically Roleca® juniper 100 mg, in addressing common digestive issues. This study focuses on symptoms such as cramps in the gastrointestinal tract, flatulence, and bloating. The trial aims to evaluate how this natural remedy might improve the quality of life for individuals suffering from persistent dyspeptic digestive complaints.

    Related diseases and areas:

  • 1 

    JX10

    ,

    The ORION study is a significant clinical trial examining JX10, a promising thrombolytic agent for patients with acute ischemic stroke who seek medical care between 4.5 and 24 hours after symptom onset. This multicenter, randomized study aims to determine whether JX10 can improve functional outcomes compared to placebo and assess its safety profile, particularly regarding the risk of brain bleeding. The trial is being conducted in two parts, testing different doses (1mg/kg and 3mg/kg) to identify the optimal treatment approach for patients with late-presenting strokes, potentially expanding treatment options beyond the current narrow time window for stroke intervention.

    Related diseases and areas: